Human cytomegalovirus US28: A functionally selective chemokine binding receptor

Infectious Disorders - Drug Targets

Volumn 9, Issue 5, 2009, Pages 548-556

  Vomaske, Jennifer ^a   Nelson, Jay A ^a   Streblow, Daniel N ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR US28; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL ACTIVATION; CELL MIGRATION; CHEMOTAXIS; CYTOMEGALOVIRUS; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVATION; LIGAND BINDING; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VIRUS GENOME; VIRUS VIRULENCE;

BINDING SITES; CHEMOKINES; CYTOMEGALOVIRUS; DRUG DESIGN; HUMANS; LIGANDS; NF-KAPPA B; PROTEIN BINDING; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TYPE C PHOSPHOLIPASES; VIRAL PROTEINS;

EID: 70349524727     PISSN: 18715265     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152609789105696     Document Type: Article

References (83)

1. Stagno, S.; Pass, R.F.; Cloud, G.; Britt, W.J.; Henderson, R.E.; Walton, P.D.; Veren, D.A. Page, F.; Alford, C.A. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA, 1986, 256(14), 1904-8.
2. Hendrix, M.; Dormans, P. H. J.; Kitseelar, P.; Bosman, F.; Bruggeman, C.A. The presence of CMV nucleic acids arterial walls of atherosclerotic and non-atherosclerotic patients. Am. J. Pathol., 1989, 134, 1151-7.
3. McDonald, K.; Rector, T.; Braunlin, E.; Kubo, S.; Olivari, M. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am. J. Cardiol., 1989, 64, 359-60.
4. Melnick, J.L.; Adam, E.; DeBakey, M.E. The link between CMV and atherosclerosis. Infect. Med., 1998, 15, 479-86.
5. Melnick, J.L.; Petrie, B.L.; Dreesman, G.R.; Burek, J.; McCollum, C.H.; DeBakey, M.E. Cytomegalovirus antigen within human arterial smooth msucle cells. Lancet, 1983, 322. 644-7.
6. Muhlestein, J.B.; Horne, B.D.; Carlquist, J.F.; Madsen, T.E.; Bair, T.L.; Pearson, R.R.; Anderson, J.L. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation, 2000, 102(16), 1917-23.
7. Speir, E.; Modali, R.; Huang, E.S.; Leon, M.B.; Shawl, F.; Finkel, T.; Epstein, S.E. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science, 1994, 265, 391-4.
8. Zhou, Y.F.; Leon, M.B.; Waclawiw, M.A.; Popma, J.J.; Yu, Z.X.; Finkel, T.; Epstein, S.E. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N. Engl. J. Med., 1996, 335(9), 624-30.
9. Harkins, L.; Volk, A.L.; Samanta, M.; Mikolaenko, I.; Britt, W.J.; Bland, K.I.; Cobbs, C.S. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet, 2002, 360(9345), 1557-63.
10. Cobbs, C.S.; Harkins, L.; Samanta, M.; Gillespie, G.Y.; Bharara, S.; King, P.H.; Nabors, L.B.; Cobbs, C.G.; Britt, W.J. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res., 2002, 62(12), 3347-50.
11. Scheurer, M.E.; Bondy, M.L.; Aldape, K.D.; Albrecht, T.; El-Zein, R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol., 2008, 116(1), 79-86.
12. Soderberg-Naucler, C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J. Intern. Med., 2006, 259(3), 219-46.
13. Michaelis, M.; Doerr, H.W.; Cinatl, J. Jr., Oncomodulation by human cytomegalovirus: evidence becomes stronger. Med. Microbiol. Immunol., 2009, 198(2), 79-81
14. Murphy, E.; Yu, D.; Grimwood, J.; Schmutz, J.; Dickson, M.; Jarvis, M.A.; Hahn, G.; Nelson, J.A.; Myers, R.M.; Shenk, TE. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc. Natl. Acad. Sci. USA, 2003, 100(25), 14976-81.
15. Attwood, T.K.; Findlay, J.B. Fingerprinting G-protein-coupled receptors. Protein Eng., 1994, 7(2), 195-203.
16. Chee, M.S.; Bankier, A.T.; Beck, S.; Bohni, R.; Brown, C.M.; Cerny, R.; Horsnell, T.; Hutchison, C.A. 3rd, Kouzarides, T.; Martignetti, J.A.; et al., Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr. Top. Microbiol. Immunol., 1990, 154, 125-69.
17. Streblow, D.N.; Orloff, S.L.; Nelson, J.A. The HCMV chemokine receptor US28 is a potential target in vascular disease. Curr. Drug Targets Infect. Disord., 2001, 1(2), 151-8.
18. Maussang, D.; Verzijl, D.; van Walsum, M.; Leurs, R.; Holl, J.; Pleskoff, O.; Michel, D.; van Dongen, G.A.; Smit, M.J. Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc. Natl. Acad. Sci. USA, 2006, 103(35), 13068-73.
19. Casarosa, P.; Bakker, R.A.; Verzijl, D.; Navis, M.; Timmerman, H.; Leurs, R.; Smit, M.J. Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28. J. Biol. Chem., 2001, 276(2), 1133-7.
20. Gao, J.L.; Murphy, P.M. Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor. J. Biol. Chem., 1994, 269(46), 28539-42.
21. Kuhn, D.E.; Beall, C.J.; Kolattukudy, P.E. The Cytomegalovirus US28 Protein Binds Multiple CC Chemokines with High Affinity. Biochem. Biophys. Res. Commun., 1995, 211(1), 325-330.
22. Billstrom, M.A.; Johnson, G.L.; Avdi, N.J.; Worthen, G.S. Intracellular signaling by the chemokine receptor us28 during human cytomegalovirus infection. J. Virol., 1998, 72(7), 5535-44.
23. Streblow, D.N.; Soderberg-Naucler, C.; Vieira, J.; Smith, P.; Wakabayashi, E.; Ruchti, F.; Mattison, K.; Altschuler, Y.; Nelson, J.A. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell, 1999, 99(5), 511-20.
24. Vomaske, J.; Melnychuk, R.; Smith, P.; Powell, J.D.; Hall, L.; DeFilippis, V.; Fruh, K.; Smit, M.; Schlaepfer, D.D.; Nelson, J.A.; Streblow, D.N. Differential ligand binding to a human cytomegalovirus chemokine receptor determines cell type-specific motility. PLoS Pathog., 2009, 5(2), 100034.
25. Urban, J.D.; Clarke, W.P.; von Zastrow, M.; Nichols, D.E.; Kobilka, B.; Weinstein, H.; Javitch, J.A.; Roth, B.L.; Christopoulos, A.; Sexton, P.M.; Miller, K.J.; Spedding, M.; Mailman, R.B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther., 2007, 320(1), 1-13.
26. Murphy, P.M.; Baggiolini, M.; Charo, I.F.; Hebert, C.A.; Horuk, R.; Matsushima, K.; Miller, L.H.; Oppenheim, J.J.; Power, C.A. International union of pharmacology. XXII. nomenclature for chemokine receptors. Pharmacol. Rev., 2000, 52(1), 145-176.
27. Baldwin, J.M. The probable arrangement of the helices in G protein-coupled receptors. EMBO J., 1993, 12(4), 1693-703.
28. Lomize, A.L.; Pogozheva, I.D.; Mosberg, H.I. Structural organization of G-protein-coupled receptors. J. Comput. Aided Mol. Des., 1999, 13(4), 325-53.
29. Unger, V.M.; Hargrave, P.A.; Baldwin, J.M.; Schertler, G.F. Arrangement of rhodopsin transmembrane alpha-helices. Nature, 1997, 389(6647), 203-6.
30. Schwartz, T.W.; T Frimurer,.M.; Holst, B.; Rosenkilde, M.M.; Elling, C.E. Molecular mechanism of 7TM receptor activation - a global toggle switch model. Annu. Rev. Pharmacol. Toxicol., 2006, 46, 481-519.
31. Farrens, D.L.; Altenbach, C.; Yang, K.; Hubbell, W.L.; Khorana, H.G. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science, 1996, 274(5288), 768-70.
32. Hubbell, W.L.; Altenbach, C.; Hubbell, C.M.; Khorana, H.G. Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv. Protein Chem., 2003, 63, 243-90.
33. Krupnick, J.G.; Benovic, J.L. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu. Rev. Pharmacol. Toxicol., 1998, 38, 289-319.
34. Benovic, J.L.; Pike, L.J.; Cerione, R.A.; Staniszewski, C.; Yoshimasa, T.; Codina, J.; Caron, M.G.; Lefkowitz, R.J. Phosphorylation of the mammalian beta-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein. J. Biol. Chem., 1985, 260(11), 7094-101.
35. Ahuja, S.K.; Lee, J.C.; Murphy, P.M. CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin-8 receptor B. Determinants of high affinity binding and receptor activation are distinct. J. Biol. Chem., 1996, 271(1), 225-32.
36. Monteclaro, F.S.; Charo, I.F. The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. J. Biol. Chem., 1996, 271(32), 19084-92.
37. Lau, E.K.; Allen, S.; Hsu, A.R.; Handel, T.M. Chemokine-receptor interactions: GPCRs, glycosaminoglycans and viral chemokine binding proteins. Adv. Protein Chem., 2004, 68, 351-391.
38. Thompson, M.D.; Cole, D.E.; Jose, P.A. Pharmacogenomics of G protein-coupled receptor signaling: insights from health and disease. Methods Mol. Biol., 2008, 448, 77-107.
39. Ballesteros, J.A.; Jensen, A.D.; Liapakis, G.; Rasmussen, S.G.; Shi, L.; Gether, U.; Javitch, J.A. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem., 2001, 276(31), 29171-7.
40. Springael, J.Y.; de Poorter, C.; Deupi, X.; Van Durme, J.; Pardo, L.; Parmentier, M. Cell Signal., 2007, 19(7), 1446-56.
41. Rovati, G.E.; Capra, V.; Neubig, R.R. The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol.Pharmacol., 2007, 71(4), 959-64.
42. Burger, M.; Burger, J.A.; Hoch, R.C.; Oades, Z.; Takamori, H.; Schraufstatter, I.U. Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor. J. Immunol., 1999, 163(4), 2017-22.
43. Auger, G.A.; Pease, J.E.; Shen, X.; Xanthou, G.; Barker, M.D. Alanine scanning mutagenesis of CCR3 reveals that the three intracellular loops are essential for functional receptor expression. Eur. J. Immunol., 2002, 32(4), 1052-8.
44. Haskell, C.A.; Cleary, M.D.; Charo, I.F. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J. Biol. Chem., 1999, 274(15), 10053-8.
45. Saidak, Z.; Blake-Palmer, K.; Hay, D.L.; Northup, J.K.; Glass, M. Differential activation of G-proteins by mu-opioid receptor agonists. Br. J. Pharmacol., 2006, 147(6), 671-80.
46. Woo, A.Y.; Wang, T.B.; Zeng, X.; Zhu, W.; Abernethy, D.R.; I.W. Wainer, Xiao, R.P. Stereochemistry of an agonist determines coupling preference of {beta}2-adrenoceptor to different G proteins in cardiomyocytes. Mol. Pharmacol., 2008, 75(1), 158-65.
47. Zhang, L.; Brass, L.F.; Manning, D.R. The Gq and G12 Families of Heterotrimeric G Proteins Report Functional Selectivity. Mol. Pharmacol., 2008, 75(1), 235-41
48. Pitcher, J.A.; Freedman, N.J.; Lefkowitz, R.J. G protein-coupled receptor kinases. Annu. Rev. Biochem., 1998, 67, 653-92.
49. Tobin, A.B.; Butcher, A.J.; Kong, K.C. Location, location, location...site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling. Trends Pharmacol. Sci., 2008, 29(8), 413-20.
50. Kelly, E.; Bailey, C.P.; Henderson, G. Agonist-selective mechanisms of GPCR desensitization. Br. J. Pharmacol., 2008, 153, (Suppl 1), S379-88.
51. Pollok-Kopp, B.; Schwarze, K.; Baradari, V.K.; Oppermann, M. Analysis of ligand-stimulated CC chemokine receptor 5 (CCR5), phosphorylation in intact cells using phosphosite-specific antibodies. J. Biol. Chem., 2003, 278(4), 2190-8.
52. Vroon, A.; Heijnen, C.J.; Kavelaars, A. GRKs and arrestins: regulators of migration and inflammation. J. Leukoc. Biol., 2006, 80(6), 1214-21.
53. Lombardi, M.S.; Kavelaars, A.; Cobelens, P.M.; Schmidt, R.E.; Schedlowski, M., Heijnen, C.J. Adjuvant arthritis induces down-regulation of G protein-coupled receptor kinases in the immune system. J. Immunol., 2001, 166(3), 1635-40.
54. Fan, J.; Malik, A.B. Toll-like receptor-4 (TLR4), signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors. Nat. Med., 2003, 9(3), 315-21.
55. Vroon, A.; Heijnen, C.J.; Lombardi, M.S.; Cobelens, P.M.; Mayor, F. Jr.; Caron, M.G.; Kavelaars, A. Reduced GRK2 level in T cells potentiates chemotaxis and signaling in response to CCL4. J. Leukoc. Biol., 2004, 75(5), 901-9.
56. Vroon, A.; Heijnen, C.J.; Raatgever, R.; Touw, I.P.; Ploemacher, R.E.; Premont, R.T.; Kavelaars, A. GRK6 deficiency is associated with enhanced CXCR4-mediated neutrophil chemotaxis in vitro and impaired responsiveness to G-CSF in vivo. J. Leukoc. Biol., 2004, 75(4), 698-704.
57. Fong, A.M.; Premont, R.T.; Richardson, R.M.; Yu, Y.R.; Lefkowitz, R.J.; Patel, D.D. Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice. Proc. Natl. Acad. Sci. USA, 2002, 99(11), 7478-83.
58. Ge, L.; Ly, Y.; Hollenberg, M.; DeFea, K. A beta-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis. J. Biol. Chem., 2003, 278(36), 34418-26.
59. Sun, Y.; Cheng, Z.; Ma, L.; Pei, G. Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J. Biol. Chem., 2002, 277(51), 49212-9.
60. Violin, J.D.; Ren, X.R.; Lefkowitz, R.J. G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer. J. Biol. Chem., 2006, 281(29), 20577-88.
61. Neote, K.; DiGregorio, D.; Mak, J.Y.; Horuk, R.; Schall, T.J. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell, 1993, 72(3), 415-25.
62. Melnychuk, R.M.; Streblow, D.N.; Smith, P.P.; Hirsch, A.J.; Pancheva, D.; Nelson, J.A. Human cytomegalovirus-encoded G protein-coupled receptor US28 mediates smooth muscle cell migration through Galpha12. J. Virol, 2004, 78(15), 8382-91.
63. Streblow, D.N.; Vomaske, J.; Smith, P.; Melnychuk, R.; Hall, L.; Pancheva, D.; Smit, M.; Casarosa, P.; Schlaepfer, D.D.; Nelson,.A. Human cytomegalovirus chemokine receptor US28-induced smooth muscle cell migration is mediated by focal adhesion kinase and Src. J. Biol. Chem., 2003, 278(50), 50456-65.
64. DeMeritt, I.B.; Milford, L.E.; Yurochko, A.D. Activation of the NF-kappaB pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter. J. Virol., 2004, 78(9), 4498-507.
65. Boomker, J.M.; The, T.H.; de Leij, L.F.; Harmsen, M.C. The human cytomegalovirus-encoded receptor US28 increases the activity of the major immediate-early promoter/enhancer. Virus Res., 2006, 118(1-2), 196-200.
66. Vischer, H.F.; Leurs, R.; Smit, M.J. HCMV-encoded G-protein-coupled receptors as constitutively active modulators of cellular signaling networks. Trends Pharmacol. Sci., 2006, 27(1), 56-63.
67. Pleskoff, O.; Casarosa, P.; Verneuil, L.; Ainoun, F.; Beisser, P.; Smit, M.; Leurs, R.; Schneider, P.; Michelson, S.; Ameisen, J.C. The human cytomegalovirus-encoded chemokine receptor US28 induces caspase-dependent apoptosis. FEBS J., 2005, 272(16), 4163-77.
68. Bodaghi, B.; Jones, T.R.; Zipeto, D.; Vita, C.; Sun, L.; Laurent, L.; Arenzana-Seisdedos, F.; Virelizier, J.L.; Michelson, S. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J. Exp. Med., 1998, 188(5), 855-66.
69. Randolph-Habecker, J.R.; Rahill, B.; Torok-Storb, B.; Vieira, J.; Kolattukudy, P.E.; Rovin, B.H.; Sedmak, D.D. The expression of the cytomegalovirus chemokine receptor homolog US28 sequesters biologically active CC chemokines and alters IL-8 production. Cytokine, 2002, 19(1), 37-46.
70. Boomker, J.M.; de Jong, E.K.; de Leij, L.F.; Harmsen, M.C. Chemokine scavenging by the human cytomegalovirus chemokine decoy receptor US28 does not inhibit monocyte adherence to activated endothelium. Antiviral. Res., 2006, 69(2), 124-7.
71. Casarosa, P.; Waldhoer, M.; LiWang, P.J.; Vischer, H.F.; Kledal, T.; Timmerman, H.; Schwartz, T.W.; Smit, M.J.; Leurs, R. CC and CX3C chemokines differentially interact with the N terminus of the human cytomegalovirus-encoded US28 receptor. J. Biol. Chem., 2005, 280(5), 3275-85.
72. Preobrazhensky, A.A.; Dragan, S.; Kawano, T.; Gavrilin, M.A.; Gulina, I.V.; Chakravarty L.; Kolattukudy, P.E. Monocyte chemotactic protein-1 receptor CCR2B is a glycoprotein that has tyrosine sulfation in a conserved extracellular N-terminal region. J. Immunol., 2000, 165(9), 5295-5303.
73. Farzan, M.; Mirzabekov, T.; Kolchinsky, P.; Wyatt, R.; Cayabyab, M.; Gerard, N.P.; Gerard, C.; Sodroski, J.; Choe, H. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell, 1999, 96(5), 667-76.
74. Waldhoer, M.; Kledal, T.N.; Farrell, H.; Schwartz, T.W. Murine cytomegalovirus (CMV), M33 and human CMV US28 receptors exhibit similar constitutive signaling activities. J. Virol, 2002, 76(16), 8161-8.
75. Waldhoer, M.; Casarosa, P.; Rosenkilde, M.M.; Smit, M.J.; Leurs, R.; Whistler, J.L.; Schwartz, T.W. The carboxyl terminus of human cytomegalovirus-encoded 7 transmembrane receptor US28 camouflages agonism by mediating constitutive endocytosis. J. Biol. Chem., 2003, 278(21), 19473-82.
76. Favre, N.; Fanelli, F.; Missotten, M.; Nichols, A.; Wilson, J.; di Tiani, M.; Rommel, C.; Scheer, A. The DRY motif as a molecular switch of the human oxytocin receptor. Biochemistry, 2005, 44(30), 9990-10008.
77. Mokros, T.; Rehm, A.; Droese, J.; Oppermann, M.; Lipp, M.; Hopken, U.E. Surface expression and endocytosis of the human cytomegalovirus-encoded chemokine receptor US28 is regulated by agonist-independent phosphorylation. J. Biol. Chem., 2002, 277(47), 45122-8.
78. Miller, W.E.; Houtz, D.A.; Nelson, C.D.; Kolattukudy, P.E.; Lefkowitz, R.J. G-protein-coupled receptor (GPCR), kinase phosphorylation and beta-arrestin recruitment regulate the constitutive signaling activity of the human cytomegalovirus US28 GPCR. J. Biol. Chem., 2003, 278(24), 21663-71.
79. Sherrill, J.D.; Miller, W.E. G protein-coupled receptor (GPCR), kinase 2 regulates agonist-independent Gq/11 signaling from the mouse cytomegalovirus GPCR M33. J. Biol. Chem., 2006, 281(52), 39796-805.
80. Fraile-Ramos, A.; Kohout, T.A.; Waldhoer, M.; Marsh, M. Endocytosis of the viral chemokine receptor US28 does not require beta-arrestins but is dependent on the clathrin-mediated pathway. Traffic, 2003, 4(4), 243-53.
81. Casarosa, P.; Menge, W.M.; Minisini, R.; Otto, C.; van Heteren, J.; Jongejan, A.; Timmerman, H.; Moepps, B.; Kirchhoff, F.; Mertens, T.; Smit, M.J.; Leurs, R. Identification of the first nonpeptidergic inverse agonist for a constitutively active viral-encoded G protein-coupled receptor. J. Biol. Chem., 2003, 278(7), 5172-8.
82. Hulshof, J.W.; Casarosa, P.; Menge, W.M.; Kuusisto, L.M.; van der Goot, H.; Smit, M.J.; de Esch, I.J. Leurs, R. Synthesis and structure-activity relationship of the first nonpeptidergic inverse agonists for the human cytomegalovirus encoded chemokine receptor US28. J. Med. Chem., 2005, 48(20), 6461-71.
83. Hulshof, J.W.; Vischer, H.F.; Verheij, M.H.; Fratantoni, S.A.; Smit, M.J.; de Esch, I.J.; Leurs, R. Synthesis and pharmacological characterization of novel inverse agonists acting on the viral-encoded chemokine receptor US28. Bioorg Med. Chem., 2006, 14(21), 7213-30.